First Genome-Wide Splice Variant Arrays Launched by Jivan Biologics
"TransExpress(TM) Whole Spliceome places Jivan at the forefront of a paradigm shift from gene arrays to splice variant arrays that will transform the half billion dollar a year microarray market," said Subha Srinivasan, PhD, CEO and Founder of Jivan Biologics.
With patent-pending technology for splice variant detection, TransExpress(TM) Whole Spliceome is the culmination of four years of research and experimental validation by Jivan scientists. It has benefited from two SBIR grants from the National Institutes of Health. Since 2002, several corporate and academic research collaborations have validated Jivan's splice array technology.
By differentiating among the splice isoforms of a gene, TransExpress(TM) Whole Spliceome multiplies the number of potential clinical biomarkers and molecular diagnostics by a factor of four or more compared to conventional gene arrays.
TransExpress(TM) Whole Spliceome includes 148,693 probes for 135,706 alternately spliced sites for 98,382 splice isoforms of 23,484 human genes.
It works with standard hybridization kits and scanners available from Agilent Technologies and other vendors.
TransExpress(TM) Whole Spliceome can be ordered online at jivanbio.com.
Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant arrays for drug development and biological research. Available as a service since 2001 and as catalogue products since 2003, Jivan's flagship TransExpress(TM) arrays are the first commercial microarrays for alternate splicing.
Jonathan Bingham
415-425-4115
Email: jbingham@jivanbio.com
jivanbio.com
Mai întâi genomul-Wide lipiturã Varianta Array lansat de Jivan Biologics - First Genome-Wide Splice Variant Arrays Launched by Jivan Biologics - articole medicale engleza - startsanatate